Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1933)	3/23/2002 8:09:14 PM
From: John McCarthy	Read Replies (1) \| Respond to of 10345

don't know if this fits ... but they did enter this agreement in 1999 ..... 07/27/1999 Merck and Elan Enter into Technology Transfer and License Agreement DUBLIN, Ireland, July 27 /PRNewswire/ -- Elan Corporation, plc (NYSE: ELN) ("Elan") today announced that it has entered into a second technology transfer and license agreement with Merck & Co., Inc. (NYSE: MRK) ("Merck"). Under the agreement, Elan will receive up to $30 million in pre-commercialization payments as well as milestone fees and royalties on sales of products formulated using Elan's proprietary NanoCrystal(TM)technology. elan.com And Merck and Elan are talking together here: See Session 4 mcnd.org John McCarthy